Bristol microscopy technology spinout NuNano has secured cash from the university’s Enterprise Fund for a second time.

Stanford-StartX Fund is among medical device developer Madorra’s backers, along with Fogarty Institute of Innovation and OneVentures Healthcare.

The Parkwalk-managed University of Bristol Enterprise Fund has joined parent IP Group to become an investor in macular degeneration-focused spinout Exonate.

Immune-Onc, an immuno-oncology therapy developer exploiting University of Texas research, has received more than $33m from investors including Stanford-StartX fund.

The Forbes-backed end-to-end healthcare product supplier has raised $88m in series A funding and added a smoking cessation service.

Nationwide Children’s Hospital spinout Celenex could fetch as much as $452m upon completion of milestones after progressing rare disease therapies conceived at the hospital’s collaborative program with Ohio State University.

The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.

Dave Rosenberg has left a managing director position at GE Ventures to head Merck Group unit M Ventures' New Business Fund.

OSF Ventures and Wanxiang Healthcare Investments are among the backers of a $45m series D round in heart monitoring platform Endotronix.

Biocon, which owns nearly a fifth in the company thanks to a licensing agreement, is in line for an exit when Equillium lists on the Nasdaq Global Market.